Shareholders who wish to participate in the general meeting must

• be entered as a shareholder in the share register maintained by Euroclear Sweden AB on Tuesday 24 June 2025; and

• notify the company of their intention to participate no later than Thursday 26 June 2025.

Notification of participation shall be made in writing by e-mail to [email protected]. The notification should state name, personal ID number or corporate registration number, address and telephone number. Any accompanying advisors (maximum two) should be notified in the same manner.

Shareholders whose shares are nominee-registered must, in order to be entitled to participate in the general meeting, temporarily register the shares in their own name, so that the shareholder is entered into the share register maintained by Euroclear Sweden AB as of the record date Tuesday 24 June 2025. Such registration may be temporary (so-called voting registration). Shareholders who wish to register shares in their own name must, in accordance with the respective nominee’s procedures, request that the nominee effects such voting registration. Voting registration requested by shareholders in such time that the registration has been completed by Thursday 26 June 2025 will be taken into account in the preparation of the share register.

Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. A person representing a legal entity shall present a certificate of registration (or equivalent authority document) evidencing that the individuals who have signed the power of attorney are authorized signatories for the shareholder. To facilitate entry to the general meeting, the original power of attorney (and any authorization documents) should be sent to the company together with the notification of participation, well in advance of the meeting.

Proxy forms are available on the company’s website, www.alzecurepharma.com.

The Board of Directors resolved on Wednesday 16 June 2025 on a new share issue, subject to the general meeting’s approval. The resolution, which the extraordinary general meeting is proposed to approve, includes the following principal terms:

The Board of Directors, or the person appointed by the Board, shall be authorised to make such minor adjustments to the resolution as may be required in connection with registration of the resolution with the Swedish Companies Registration Office, Euroclear Sweden AB or due to other formal requirements.

The shareholders are reminded of their right to request information from the Board of Directors and the CEO in accordance with Chapter 7, Section 32 of the Swedish Companies Act

For information on how your personal data is processed, please refer to https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

DOCUMENTS

The Board of Directors’ complete resolution, together with documentation pursuant to Chapter 13, Section 6 of the Swedish Companies Act, is available to shareholders and will be sent immediately and free of charge to shareholders who request it and provide their postal address. Such request shall be made in writing to Hälsovägen 7, 141 57 Huddinge or by e-mail to [email protected].

__________________

Stockholm, June 2025

AlzeCure Pharma AB (publ)
The Board of Directors

This is an office translation of the Swedish original. In case of differences the Swedish original text shall prevail.